Defining On-Treatment Remission in Plaque Psoriasis
JAMA Dermatology · 2025
DOI: 10.1001/jamadermatol.2025.1625 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, 2025. Verfasst von April W Armstrong und 39 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles. Hauptthemen laut MEDLINE: Psoriasis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Importance Defining on-treatment remission in plaque psoriasis is important for benchmarking patient responses to therapies. This also helps to facilitate shared understanding, align treatment expectations, and enable more effective psoriasis management.
Objective
To establish a consensus-based definition of on-treatment remission for plaque psoriasis through a multistage Delphi initiative. Evidence Review The Remission Workgroup from the medical board and scientific advisory board of the National Psoriasis Foundation engaged various stakeholders, both US based and international, to participate in the consensus process. Following a working group meeting to determine the overall consensus approach, a systematic review of remission definitions in the current literature was performed. This review helped to inform the content of consensus materials. The consensus effort involved 2 stages: pre-Delphi interviews and surveys to inform the Delphi questions, followed by a Delphi exercise with physicians to define on-treatment remission for plaque psoriasis. Outcome measures considered included body surface area (BSA), Investigator Global Assessment (IGA), the product of the Physician Global Assessment and body surface area (PGA × BSA), and Psoriasis Area and Severity Index (PASI) score at various cutoff levels and time points.
Findings
The consensus process involved 92 stakeholders, including dermatologists, rheumatologists, researchers, patients, payers, and life sciences professionals. In the pre-Delphi interviews and surveys, patients emphasized that on-treatment remission meant the absence of psoriasis signs and symptoms while recieving therapy. Payers expressed that defining remission is important for long-term treatment coverage. Following the Delphi exercise and discussion with participating physicians specializing in psoriatic disease management, on-treatment remission in plaque psoriasis was defined as patients maintaining a BSA of 0% or IGA of 0 for at least 6 months while on treatment. Conclusions and Relevance Through a Delphi consensus process, on-treatment remission for plaque psoriasis was defined as patients maintaining a BSA involvement of 0% or IGA of 0 for at least 6 months while on treatment. This clear and standardized benchmark is applicable to both research and practice settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles.
- National Psoriasis Foundation, Alexandria, Virginia.
- Division of Rheumatology, Departments of Dermatology and Medicine, O'Donnell School of Public Health, University of Texas Southwestern Medical Center, Dallas.
- University of Hawaii at Manoa John A. Burns School of Medicine, Honolulu.
- Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
- Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands.
Zitieren
APA
Armstrong, A. W., Gondo, G. C., Merola, J. F., Roberts, A. M., Pérez-Chada, L. M., Balak, D. M. W., Eakin, G. S., Read, C., Le, S. T., Gutierrez, Y., Bhutani, T., Blauvelt, A., Duffin, K. C., Fakharzadeh, S., Feldman, S. R., Gelfand, J. M., Gladman, D. D., Glick, B., Green, L. J., …, & Remission Workgroup of the National Psoriasis Foundation (2025). Defining On-Treatment Remission in Plaque Psoriasis. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2025.1625
Vancouver
Armstrong AW, Gondo GC, Merola JF, Roberts AM, Pérez-Chada LM, Balak DMW, et al. Defining On-Treatment Remission in Plaque Psoriasis. JAMA Dermatology. 2025. doi:10.1001/jamadermatol.2025.1625
BibTeX
@article{Armstrong2025,
author = {Armstrong, April W and Gondo, George C and Merola, Joseph F and Roberts, Alyssa M and Pérez-Chada, Lourdes M and Balak, Deepak M W and Eakin, Guy S and Read, Charlotte and Le, Stephanie T and Gutierrez, Yasmin and Bhutani, Tina and Blauvelt, Andrew and Duffin, Kristina Callis and Fakharzadeh, Steven and Feldman, Steven R and Gelfand, Joel M and Gladman, Dafna D and Glick, Brad and Green, Lawrence J and Han, George and Hawkes, Jason E and Hwang, Samuel T and Johnsen, Nicole and Kalb, Robert E and Kircik, Leon and Langley, Richard G and Lebwohl, Mark G and Lewitt, G Michael and Maverakis, Emanual and Prussick, Ronald and Reddy, Soumya M and Rosen, Cheryl F and Scher, Jose U and Siegel, Evan L and Wallace, Elizabeth B and Weinberg, Jeffrey M and Yamauchi, Paul S and Yosipovitch, Gil and Liao, Wilson and Remission Workgroup of the National Psoriasis Foundation, Remission Workgroup of the National Psoriasis Foundation},
title = {Defining On-Treatment Remission in Plaque Psoriasis},
journal = {JAMA Dermatology},
year = {2025},
doi = {10.1001/jamadermatol.2025.1625}
}
EUVIMED